 TEL AVIV, Israel, Feb. 09, 2021 GLOBE NEWSWIRE -- InspireMD, Inc. NYSE American: NSPR, developer of the CGuardTM Embolic Prevention System EPS for the prevention of stroke caused by carotid artery disease, announced today the appointment of Chris Metzger, M.D., system chair of clinical research at Ballad Health System in Eastern Tennessee as the principal investigator for its planned FDA registration trial for CGuard EPS. 